US Oncology Research Collaborates with BioMarin Pharmaceutical to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients

25-10-2013 Business Wire HealthComments (0)

BioMarin PharmaceuticalOncologyPharmaceutical

US Oncology Research is collaborating with BioMarin Pharmaceutical to offer a groundbreaking Phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top